Impact of non-adherence on the safety and efficacy of uric acid lowering therapies in the treatment of gout
British journal of clinical pharmacology | 10 Sep 2017
D Hill-McManus, E Soto, S Marshall, S Lane and D Hughes
Dual-urate lowering therapy (ULT) with xanthine oxidase inhibitor and uricosuric medications is a treatment option for severe gout. Uricosurics can cause hyperuricosuria, a risk factor for nephrolithiasis and acute uric acid nephropathy. The aims of this study were to simulate the relation between suboptimal drug adherence and efficacy, and to quantify the risk of hyperuricosuria in gout patients receiving mono and dual-ULTs.
* Data courtesy of Altmetric.com